Rejuvenated Battle Between Celera and HGP Rouses Novel Ethical Dilemmas | GenomeWeb

NEW YORK, March 6 - Celera Genomics has rolled up its sleeves. But the renewed public battle between it and the Human Genome Project may have complex ethical implications that might shape the future of genomic research.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.